









Markets
/
Stocks
/
nasdaq-stro
/

Sutro Biopharma Inc

STRO

15.520USD

+0.920+6.30%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

132.08MMarket Cap

LossP/E TTM



Sutro Biopharma Inc

15.520

+0.920+6.30%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sutro Biopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Sutro Biopharma Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 121 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.86.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sutro Biopharma Inc's Score

Industry at a Glance

Industry Ranking

121 / 392

Overall Ranking

257 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sutro Biopharma Inc Highlights

StrengthsRisks

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 62.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 62.04M.

Fairly Valued

The company’s latest PE is -0.60, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.62M shares, decreasing 35.15% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 13.49K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

33.857

Target Price

+131.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Sutro Biopharma Inc is 5.69, ranking 335 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 9.69M, representing a year-over-year increase of 13.77%, while its net profit experienced a year-over-year increase of 16.54%.

Score

Industry at a Glance

Previous score

5.69

Change



Financials

5.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.08

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Sutro Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Sutro Biopharma Inc is 7.07, ranking 178 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.60, which is -69.91% below the recent high of -0.18 and -503.98% above the recent low of -3.60.

Score

Industry at a Glance

Previous score

7.07

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 121/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Sutro Biopharma Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 100.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

33.857

Target Price

+131.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Sutro Biopharma Inc

STRO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Sutro Biopharma Inc is 9.33, ranking 16 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.39 and the support level at 11.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.09

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.318

Neutral

RSI(14)

61.726

Neutral

STOCH(KDJ)(9,3,3)

52.947

Buy

ATR(14)

1.583

High Vlolatility

CCI(14)

11.894

Neutral

Williams %R

40.402

Buy

TRIX(12,20)

1.372

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

14.988

Buy

MA10

15.268

Buy

MA20

14.425

Buy

MA50

11.696

Buy

MA100

10.489

Buy

MA200

9.569

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Sutro Biopharma Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.92%, representing a quarter-over-quarter increase of 6.64%. The largest institutional shareholder is The Vanguard, holding a total of 375.79K shares, representing 4.41% of shares outstanding, with 15.37% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Affinity Asset Advisors LLC

658.38K

+774.66%

Suvretta Capital Management, LLC

648.83K

Kynam Capital Management LP

508.81K

Millennium Management LLC

452.44K

-4.39%

The Vanguard Group, Inc.

Star Investors

368.30K

-10.50%

Acadian Asset Management LLC

338.93K

+11.41%

Velan Capital Investment Management LP

312.00K

+1.96%

Tang Capital Management, LLC

282.87K

+10.43%

Merck & Co Inc

272.35K

Vestal Point Capital, LP

260.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sutro Biopharma Inc is 1.04, ranking 352 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.